Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent [PDF]
Frontiers in Pharmacology, 2020 B-cell lymphoma 2 (BCL-2) family proteins primarily work as a programmed cell death regulator, whereby multiple interactions between them determine cell survival.
Nur Najmi Mohamad Anuar, Azizah Ugusman
exaly +5 more sources
Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax [PDF]
Cells, 2021 Cancer-associated fibroblasts (CAFs) are key actors in regulating cancer progression. They promote tumor growth, metastasis formation, and induce drug resistance. For these reasons, they are emerging as potential therapeutic targets.
Leopoldo Sitia +2 more
exaly +7 more sources
The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke [PDF]
PharmaceuticalsBackground/Objectives: Senescence has been recently described in brain cells following ischemic stroke. The potential of targeting senescence as an effective therapeutic approach in the treatment of ischemic stroke requires further investigation.
Dianoush Falahatgaroshibi +6 more
doaj +2 more sources
Pharmaceutics, 2021 Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the
Azizah Ugusman +2 more
exaly +3 more sources
Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer [PDF]
Frontiers in Cell and Developmental BiologyIntroductionTherapy-induced Senescence (TIS) can potentially influence breast cancer treatment outcomes, in part by contributing to disease recurrence; hence, the utilization of senescence-eliminating agents (i.e., senolytics) is considered as a possible
Homood M. As Sobeai +18 more
doaj +2 more sources
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. [PDF]
PLoS ONE, 2014 While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis.
Dennie T Frederick +15 more
doaj +6 more sources
Navitoclax acts synergistically with irradiation to induce apoptosis in preclinical models of H3K27M-altered diffuse midline glioma [PDF]
Scientific ReportsDiffuse midline gliomas (DMGs) with histone H3K27M mutations represent a devastating paediatric brain cancer characterised by abysmal prognosis and limited treatment options.
Ashley Vardon +26 more
doaj +2 more sources
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis [PDF]
Nature CommunicationsMycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis.
Medha Singh +13 more
doaj +2 more sources
Repurposing BCL2 inhibitors: Venetoclax protects against acinar cell necrosis in acute pancreatitis by promoting apoptosis [PDF]
Cell Death and DiseaseAcute pancreatitis (AP), a severe inflammatory disorder of the pancreas, lacks effective pharmacological treatment. The disease is primarily driven by necrosis of pancreatic acinar cells (PACs), which intensifies inflammation and organ injury. This study
Jacek J. Litewka +12 more
doaj +2 more sources
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy [PDF]
HemaSphereThe B‐cell lymphoma 2 (BCL‐2) inhibitor venetoclax (VEN) in combination with hypomethylating agents (HMAs) has improved treatment outcomes for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy and is increasingly used in the relapsed/
Ida Vänttinen +17 more
doaj +2 more sources